+86 16650237703
Author:Kangdi 19-08-2026
Audience: B2B buyers, regulatory affairs managers, brand owners, and product developers seeking to understand FDA 21 CFR 348 OTC monograph framework and select compliant active ingredients for pain patch OEM in 2026.
Reading time: 14 minutes.
What you'll get: 5 active ingredient categories covered under 21 CFR 348, 4 monograph framework requirements, 5 ingredient selection criteria, 5-step compliant ingredient selection workflow, and 5 FAQ including monograph vs NDA pathway decisions.
1. 5 Active Ingredient Categories Under 21 CFR 348
FDA 21 CFR Part 348 covers external analgesic OTC monograph products. Pain patch OEM products fall under 5 active ingredient categories within this monograph.
Category 1 — Counterirritant active ingredients
Counterirritants create sensation (cooling, warming, tingling) that masks pain signal. Recognized monograph active ingredients: menthol (1–16%), methyl salicylate (10–30%), camphor (3–11%), capsicum / capsaicin (0.025–0.25%), eucalyptus oil (0.5–3%), turpentine oil (0.5–3%). Pain patch applications: cooling menthol patch, warming capsaicin patch, methyl salicylate muscle patch.
Category 2 — Topical anesthetic active ingredients
Topical anesthetics numb the skin area to relieve surface pain. Recognized monograph active ingredients: lidocaine (2–4%), benzocaine (5–20%), prilocaine (2.5%), tetracaine (2–4%), dibucaine (0.25–1%). Pain patch applications: lidocaine pain relief patch, post-procedure numbing patch.
Category 3 — Topical analgesic combinations
Combinations of counterirritant + topical anesthetic + other monograph ingredients. Recognized combinations: menthol + camphor (cooling + decongestant), methyl salicylate + menthol (warming + cooling), capsaicin + menthol (warming + cooling). Combinations must comply with individual ingredient concentration limits.
Category 4 — External analgesic with skin protectant
Some pain patches combine external analgesic with skin protectant ingredients (e.g., allantoin, dimethicone). Recognize as combination monograph product. Documentation requirements: both external analgesic monograph (Part 348) and skin protectant monograph (Part 347) compliance.
Category 5 — External analgesic with anti-itch or antifungal
Less common combinations: analgesic + anti-itch (e.g., diphenhydramine) or analgesic + antifungal (e.g., tolnaftate). Must comply with relevant monograph parts. Pain patch applications: limited but growing (e.g., anti-itch pain patch for insect bite relief).
2. 4 OTC Monograph Framework Requirements
Requirement 1 — Active ingredient recognition
Active ingredient must be GRASE (Generally Recognized As Safe and Effective) under 21 CFR 348. Use only monograph-recognized active ingredients at monograph-specified concentration ranges. Avoid non-monograph ingredients or non-monograph concentrations.
Requirement 2 — Dosage form and route
Pain patch is a recognized topical dosage form under 21 CFR 348.10. Route of administration: topical (skin application only). Dosage form: patch, plaster, pad, or poultice. Comply with patch-specific monograph requirements.
Requirement 3 — Labeling compliance
Labeling must comply with 21 CFR Part 201. External analgesic monograph labeling requirements (21 CFR 348.50, 348.60, 348.70, 348.80): indication statement (e.g., "for the temporary relief of minor aches and pains"), warning statements (e.g., "for external use only", "do not use on wounds or damaged skin"), directions for use, active ingredient declaration.
Requirement 4 — Manufacturing and quality
Manufacturing must comply with 21 CFR 210/211 GMP for OTC drug products. Facility Registration with FDA (annual, USD 5,000–15,000). Drug listing (per SKU, annual). Quality system: incoming material testing, in-process testing, finished product testing, stability program, complaint handling, recall procedure.
3. 5 Active Ingredient Selection Criteria
Choose active ingredients for pain patch OEM using 5 selection criteria.
Criterion 1 — Monograph compliance
Select only GRASE active ingredients under 21 CFR 348. Verify concentration within monograph-specified range. Confirm no prohibited combinations. Use FDA's monograph database for verification.
Criterion 2 — Target market positioning
Cooling patch: menthol-based (consumer-friendly, broad appeal). Warming patch: capsaicin-based (athletes, chronic pain positioning). Numbing patch: lidocaine-based (clinical positioning, premium). Multi-action patch: menthol + methyl salicylate + camphor combinations.
Criterion 3 — Clinical efficacy and safety profile
Menthol: well-tolerated, cooling sensation, GRASE, broad use. Capsaicin: warming, effective for chronic pain, requires careful concentration control to avoid irritation. Lidocaine: numbing, effective for surface pain, requires concentration precision. Methyl salicylate: warming, anti-inflammatory, must avoid aspirin-allergy patients.
Criterion 4 — Regulatory cost and time-to-market
Monograph pathway: lower cost (USD 50,000–150,000), faster timeline (12–18 months). NDA pathway (for non-monograph ingredients): higher cost (USD 5–10 million), longer timeline (5–10 years). For first-time B2B buyers, monograph pathway is recommended for time-to-market and capital efficiency.
Criterion 5 — Manufacturing complexity and cost
Menthol: low cost, easy formulation, stable. Capsaicin: moderate cost, requires careful handling (irritant), moderate stability. Lidocaine: moderate cost, requires concentration precision, moderate stability. Methyl salicylate: low cost, easy formulation, moderate stability (odor).
4. 5-Step Compliant Ingredient Selection Workflow
Step 1 — Define target product positioning (week 1)
Document: target indication (muscle, joint, nerve, back), consumer demographic, retail price point, competitive landscape, brand positioning. This drives ingredient selection.
Step 2 — Identify monograph-allowed ingredient candidates (week 2)
Consult 21 CFR 348 monograph for active ingredients allowed. List candidate ingredients with concentration ranges. Cross-reference with FDA GRASE database.
Step 3 — Evaluate ingredients on 5 criteria (week 3)
Score each candidate ingredient on: monograph compliance, target market fit, clinical efficacy, regulatory cost / time, manufacturing complexity. Calculate weighted score. Select top 1–2 ingredients.
Step 4 — Formulation development (week 4–12)
Develop formulation with selected active ingredients. Lab-scale batch, stability testing, in-vitro permeation testing, skin irritation testing. Iterate formulation based on testing results.
Step 5 — Regulatory filing and labeling (week 12–18)
Finalize formulation, finalize labeling (indication, warnings, directions, ingredients). Submit Facility Registration renewal if needed. Drug listing submission. Final packaging compliance review. Launch in US market.
5. FAQ (5 Questions)
FAQ 1: What is the difference between OTC monograph and NDA pathway?
OTC monograph (21 CFR 348): for ingredients GRASE under monograph, no pre-market approval required, lower cost (USD 50K–150K), faster (12–18 months). NDA (New Drug Application): for non-monograph ingredients or indications, requires FDA pre-market approval, higher cost (USD 5–10M), longer (5–10 years). Monograph is preferred for typical pain patch OEM; NDA only for novel ingredients or indications.
FAQ 2: What concentration limits apply to menthol in cooling patches?
Menthol concentration in cooling pain patches: typically 1–16% under 21 CFR 348 monograph. Lower range (1–5%): mild cooling, consumer-grade. Mid range (5–10%): standard cooling, OTC patch. Upper range (10–16%): strong cooling, professional / clinical-grade. Above 16%: considered non-monograph, may require NDA. Confirm with FDA monograph for current allowable range.
FAQ 3: Can I use lidocaine + menthol combination in a single patch?
Yes, lidocaine + menthol combination is allowed under 21 CFR 348 if both active ingredients are within their respective monograph concentration ranges. Lidocaine: 2–4% (topical anesthetic). Menthol: 1–16% (counterirritant). Combination must be labeled with both indications: "topical anesthetic" and "cooling counterirritant". Manufacturing must comply with both ingredient specifications.
FAQ 4: How do I handle non-US market pain patch formulations?
Non-US markets have different regulatory frameworks. EU: EU MDR 2017/745 (Class IIa medical device) for pain patches with medical claims; EU CPNP notification for cosmetic claims. GCC: SFDA / MOH product registration. China: NMPA medical device license for Class II medical device pain patches. Canada: Health Canada Drug Identification Number (DIN) or Natural Product Number (NPN). Each market has distinct monograph / regulatory framework. Develop market-specific formulation if needed.
FAQ 5: What labeling mistakes do B2B buyers commonly make?
Common labeling mistakes: (1) Unapproved indication claims (e.g., "treats arthritis" vs monograph-allowed "temporary relief of minor aches and pains"). (2) Missing required warnings (e.g., "for external use only", "do not use on broken skin"). (3) Improper active ingredient declaration format. (4) Missing directions for use. (5) Improper packaging (non-child-resistant if required). (6) Missing or wrong Drug Facts panel format. Engage regulatory consultant before label finalization to avoid FDA 21 CFR 330 compliance issues.
6. Conclusion
FDA 21 CFR 348 OTC monograph covers 5 active ingredient categories for pain patch OEM: counterirritants (menthol, methyl salicylate, camphor, capsaicin), topical anesthetics (lidocaine, benzocaine), combinations, skin protectant combinations, and anti-itch / antifungal combinations. Comply with 4 OTC monograph framework requirements: active ingredient recognition, dosage form, labeling, manufacturing quality (21 CFR 210/211 GMP + Facility Registration). Select active ingredients based on 5 criteria: monograph compliance, target market positioning, clinical efficacy, regulatory cost / time, manufacturing complexity. Follow 5-step compliant ingredient selection workflow: define positioning, identify candidates, evaluate on criteria, formulation development, regulatory filing and labeling. For deeper analysis of compliance documentation, see Pain Patch OEM Compliance Documentation Checklist. For regulatory comparison across markets, see Pain Relief Patch OEM Compliance Guide. For supplier qualification, see Pain Patch OEM Factory Audit Guide.
If you would like to discuss pain patch OEM OTC monograph compliance, active ingredient selection, or US regulatory filing strategy, contact Henan Kangdi Medical Devices at kangdimedical@gmail.com or +86 155 1754 1011. We provide OTC monograph-compliant formulation development, 21 CFR 348 / 210 / 211 GMP manufacturing, FDA Facility Registration support, and labeling compliance review for US market launch.
References
- 21 CFR 348 — External analgesic drug products: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-348
- FDA OTC Monographs: https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monographs
- 21 CFR 210/211 — cGMP for finished pharmaceuticals: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-210
- FDA Facility Registration: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-establishment-registration
- 21 CFR 201 — Drug labeling: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201
- EU MDR 2017/745 — Medical Device Regulation: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745
- PubChem — Menthol: https://pubchem.ncbi.nlm.nih.gov/compound/Menthol
- PubChem — Capsaicin: https://pubchem.ncbi.nlm.nih.gov/compound/Capsaicin
- PubChem — Lidocaine: https://pubchem.ncbi.nlm.nih.gov/compound/Lidocaine
- PubChem — Methyl salicylate: https://pubchem.ncbi.nlm.nih.gov/compound/Methyl-salicylate
- PubMed — Topical analgesic efficacy: https://pubmed.ncbi.nlm.nih.gov/
- ISO 13485:2016 — Medical devices quality management systems: https://www.iso.org/standard/59752.html
- China NMPA — Medical device manufacturing license: https://www.nmpa.gov.cn/
- FDA GRASE database: https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs
- ISO 22716:2007 — Cosmetic GMP: https://www.iso.org/standard/36494.html
Contact: For OEM/ODM inquiries, email kangdimedical@gmail.com or call +86 155 1754 1011.Updated: August 2026. Information current as of publication date. FDA monograph frameworks, ingredient concentration limits, and labeling requirements evolve continuously. Always verify current 21 CFR regulations, FDA guidance documents, and GRASE status with up-to-date regulatory review before finalizing formulation and labeling decisions.